<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02093663</url>
  </required_header>
  <id_info>
    <org_study_id>SPD476-319</org_study_id>
    <secondary_id>2013-001744-65</secondary_id>
    <nct_id>NCT02093663</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis</brief_title>
  <acronym>PACE</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis, in Both Acute and Maintenance Phases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <brief_summary>
    <textblock>
      To assess clinical response to MMX mesalamine/mesalazine between a low and high dose in
      children and adolescents aged 5-17 years with mild to moderate Ulcerative Colitis (UC) or who
      are in remission.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2014</start_date>
  <completion_date type="Actual">November 28, 2018</completion_date>
  <primary_completion_date type="Actual">November 28, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinical Response During Double-Blind Acute Phase at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Clinical response was defined as partial ulcerative colitis disease activity index (UC-DAI) score &lt; or =1 with rectal bleeding = 0, stool frequency &lt; or =1, and physician's global assessment (PGA = 0). Number of participants with clinical response were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Response During Double-blind Maintenance Phase at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Clinical response was defined as partial UC-DAI &lt;=1 with (rectal bleeding = 0, stool frequency &lt; or =1, and PGA = 0). Number of participants who had maintained clinical response were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical and Endoscopic Response During Double Blind Acute Phase at Week 8 Using Central Reading</measure>
    <time_frame>Week 8</time_frame>
    <description>Clinical and endoscopic response was defined as UC-DAI &lt;=2 with rectal bleeding = 0 and stool frequency &lt;=1, and PGA = 0, and with mucosal healing (endoscopy score &lt;=1) at least a 1 point reduction in endoscopy score from baseline based on central reading. Participants with missing data at week 8 were assumed not to had a clinical response. Participants who completed week 8 but did not have central reading endoscopies at both baseline and week 8 were excluded. Number of participants with clinical and endoscopic response were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical and Endoscopic Response During Double Blind Acute Phase at Week 8 Using Local Reading</measure>
    <time_frame>Week 8</time_frame>
    <description>Clinical and endoscopic response was defined as UC-DAI &lt; or =2 with rectal bleeding = 0 and stool frequency &lt; or =1, and PGA = 0, and with mucosal healing (endoscopy score &lt; or =1) at least a 1 point reduction in endoscopy score from baseline based on local reading. Participants with missing data at week 8 were assumed not to had a clinical response. Participants who completed week 8 but did not have local reading endoscopies at both baseline and week 8 were excluded. Number of participants with clinical and endoscopic response were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Ulcerative Colitis Scale (DUCS) Score During Double-Blind Acute Phase</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>DUCS score was to measure 7 specific signs or symptom and one impact (abdominal pain, nocturnal stool, daytime stool, blood in stool, diarrhea, urgency, tiredness) of UC with each item score ranged from 0 (worst) to 10 (best) with the overall score ranged from 0 (worst) to 70 (best) based on the responses. Change in the DUCS score from baseline to Week 8 during DBA phase were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Improvement in Pediatric Ulcerative Colitis Activity Index (PUCAI) Score During Double-blind Acute Phase at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>PUCAI was a physician-administered measure that focuses on 6 key signs and symptoms of UC and activity limitations producing a total score ranging from 0-85 with higher scores being worse. Recommended cut-off scores to differentiate disease activity are &lt; 10 (remission); 11-30 (mild); 31-64 (moderate) and &gt; 65 (severe). Participants with an improvement (change of greater than or equal to [&gt; or =] 20 points) in PUCAI score. Number of participants with improvement in PUCAI score during Double-blind Acute Phase at Week 8 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical and Endoscopic Response During Double-Blind Maintenance Phase at Week 26 Using Central Reading</measure>
    <time_frame>Week 26</time_frame>
    <description>Clinical and endoscopic response was defined as UC-DAI &lt; or =2 with rectal bleeding=0, stool frequency &lt; or =1, PGA=0, and with mucosal healing (endoscopy score &lt; or =1) based on central reading at Week 26. Number of participants with clinical and endoscopic response during double-blind maintenance phase at Week 26 using central reading were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical and Endoscopic Response During Double-Blind Maintenance Phase at Week 26 Using Local Reading</measure>
    <time_frame>Week 26</time_frame>
    <description>Clinical and endoscopic response was defined as UC-DAI &lt; or = 2 with rectal bleeding=0, stool frequency &lt; or = 1, PGA=0, and with mucosal healing (endoscopy score &lt; or = 1) based on local reading. Number of participants who had maintained clinical and endoscopic response during double-blind maintenance phase at week 26 using local reading were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Ulcerative Colitis Scale (DUCS) Score During Double-Blind Maintenance Phase</measure>
    <time_frame>Baseline, Week 13, and Week 26</time_frame>
    <description>DUCS score was to measure 7 specific signs or symptom and one impact (abdominal pain, nocturnal stool, daytime stool, blood in stool, diarrhea, urgency, tiredness) of UC with each score range from 0 (worst) to 10 (best) with the overall score ranging from 0 (worst) to 70 (best) based on the responses. Change from Baseline in DUCS score during double-blind maintenance phase at week 13 and Week 26 wwere reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Remission at Pediatric Ulcerative Colitis Activity Index (PUCAI) Score During Double-Blind Maintenance Phase at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>PUCAI was a physician-administered measure that focuses on 6 key signs and symptoms of UC and activity limitations producing a total score ranging from 0-85 with higher scores being worse. Recommended cut-off scores to differentiate disease activity are &lt; 10 (remission); 11-30 (mild); 31-64 (moderate) and &gt; 65 (severe). Number of participants with remission at PUCAI score during double-blind maintenance phase at week 26 were reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>MMX Mesalamine/Mesalazine (Low Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (&lt;=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (&gt;) 23 kg to &lt;= 35 kg; 1800 mg/day for participants weighing &gt; 35 kg to &lt;= 50 kg; 2400 mg/day for participants weighing &gt; 50 kg to &lt;= 90 kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMX Mesalamine/Mesalazine (High Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to &lt;= 23 kg; 2400 mg/day for participants weighing &gt; 23 kg to &lt;= 35 kg; 3600 mg/day for participants weighing &gt; 35 kg to &lt;= 50 kg; 4800 mg/day for participants weighing &gt; 50 kg to &lt;= 90 kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMX Mesalamine/Mesalazine (Low Dose)</intervention_name>
    <description>Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (&lt;=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (&gt;) 23 kg to &lt;= 35 kg; 1800 mg/day for participants weighing &gt; 35 kg to &lt;= 50 kg; 2400 mg/day for participants weighing &gt; 50 kg to &lt;= 90 kg.</description>
    <arm_group_label>MMX Mesalamine/Mesalazine (Low Dose)</arm_group_label>
    <other_name>Lialda</other_name>
    <other_name>Mezavant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMX Mesalamine/Mesalazine (High Dose)</intervention_name>
    <description>Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to &lt;= 23 kg; 2400 mg/day for participants weighing &gt; 23 kg to &lt;= 35 kg; 3600 mg/day for participants weighing &gt; 35 kg to &lt;= 50 kg; 4800 mg/day for participants weighing &gt; 50 kg to &lt;= 90 kg.</description>
    <arm_group_label>MMX Mesalamine/Mesalazine (High Dose)</arm_group_label>
    <other_name>Mezavant</other_name>
    <other_name>Lialda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to voluntarily provide written, signed, and dated (personally or via a legally
             authorized representative [LAR]) informed consent or assent as applicable to
             participate in the study.

          2. Subject's parent/LAR demonstrates an understanding, ability, and willingness to fully
             comply with study procedures and restrictions.

          3. Male and female children and adolescents aged 5-17 years, inclusive.

          4. Body weight 18-90kg.

          5. Male, or non-pregnant, non-lactating female who agrees to comply with any applicable
             contraceptive requirements of the protocol or females of non-childbearing potential.

          6. Diagnosed with mild to moderate UC, established by sigmoidoscopy or colonoscopy with
             compatible histology. Screened subjects may also have an unconfirmed diagnosis of mild
             to moderate UC; however the diagnosis of mild to moderate UC must have been
             established by sigmoidoscopy or colonoscopy with compatible histology prior to
             baseline visit.

          7. Subject is able to swallow the investigational product whole.

             Double-blind Acute Phase:

          8. Partial UC-DAI score ≥2 (a combined rectal bleeding and stool frequency score ≥1 and
             PGA=1 or 2) at the Baseline Visit, for which 5-ASA would be used as part of normal
             treatment.

          9. If the subject is on 5-ASA treatment prior to study entry, then the dose must be
             stable. Stable therapy is defined as no change in dose, or no initiation of 5-ASA,
             from the onset of the current acute flare through discontinuation of therapy (required
             at the Baseline Visit).

             Double-blind Maintenance Phase:

         10. Partial UC-DAI ≤1 (rectal bleeding=0, stool frequency ≤1, and PGA=0) at the Baseline
             Visit.

        Exclusion Criteria:

          1. Severe UC (defined by PGA=3).

          2. Crohn's disease, bleeding disorders, active peptic ulcer disease, or UC known to be
             confined to the rectum (isolated rectal proctitis).

          3. Asthma, only if known to be 5 ASA sensitive.

          4. Positive stool culture for enteric pathogens (including Salmonella, Shigella,
             Yersinia, Aeromonas, Plesiomonas, or Campylobacter). Clostridium difficile toxin, ova,
             or parasites present.

          5. Systemic or rectal corticosteroid use within 4 weeks prior to the Screening Visit.
             Topical, intranasal, or inhaled use is not exclusionary.

          6. Immunomodulator (6-mercaptopurine, azathioprine) use within 6 weeks prior to the
             Screening Visit.

          7. History of biologic (eg, anti-tumor necrosis factor agents, integrin receptor
             antagonists) use at any time.

          8. Antibiotic use within 7 days prior to the Screening Visit.

          9. Any anti-inflammatory drugs, not including 5-ASA treatment but including non-steroidal
             anti-inflammatory drugs such as aspirin, COX-2 inhibitors or ibuprofen, within 7 days
             prior to the Screening Visit unless used at over-the-counter levels for &lt;3 days.
             However, prophylactic use of a stable dose of aspirin up to 325mg/day for cardiac
             disease is permitted.

         10. Prebiotic/probiotic use within 7 days prior to the Screening Visit. Yogurt products
             are permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland Children's Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newton Wellesley Hospital</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Children's Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Gastroenterology</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Medical Center</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Pediatric Gastroenterology &amp; Nutrition</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1C9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont</name>
      <address>
        <city>Korányi</city>
        <state>Szeged</state>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Janos Korhaz És Észak-budai Egyesitett Korha</name>
      <address>
        <city>Budapest</city>
        <zip>H-1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Pandy Kalman Korhaz</name>
      <address>
        <city>Gyula</city>
        <zip>H-5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baz Megyei Korhaz Es Egyetemi Oktatokorhaz</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktato Korhaz</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>85025</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Corporation</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Medical Centre</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Dzieciecy Szpital Kliniczny im. Ludwika Zamenhofa</name>
      <address>
        <city>Bialystok</city>
        <zip>15-247</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Pediatrii Gastroenterologii I Zywienia</name>
      <address>
        <city>Krakow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Gastroenterologii I Pediatrii</name>
      <address>
        <city>Lodz</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital Dzieciecy</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Lekarski-Bartosz Korczowski</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Gastroenterologii I Hepatologii</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny We Wrocławiu</name>
      <address>
        <city>Wrocław</city>
        <zip>50-369</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detská fakultná nemocnica s poliklinikou</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>974 09</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Bratislava</city>
        <zip>833 40</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitna Nemocnica Martin</name>
      <address>
        <city>Martin</city>
        <zip>03659</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>LI2 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust, Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 17, 2014</study_first_submitted>
  <study_first_submitted_qc>March 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2014</study_first_posted>
  <results_first_submitted>October 16, 2019</results_first_submitted>
  <results_first_submitted_qc>January 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2020</results_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild</keyword>
  <keyword>Moderate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT02093663/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT02093663/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 50 study centers and 33 sites consented at least 1 participant between 12 December 2014 (first participant first visit) and 28 November 2018 (last participant last visit).</recruitment_details>
      <pre_assignment_details>Study was conducted in three phases as double blind acute (DBA), open label acute (OLA), and double blind maintenance (DBM) phase. Overall, 107 participants were enrolled and entered into DBA or DBM directly and eligible participants entered into DBM phase after DBA or OLA through DBA. Total, 105 participants received treatment and 65 completed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Double-Blind Acute (DBA) Phase: Low Dose</title>
          <description>Participants with partial UC-DAI &gt; or =2 and mucosal appearance = 2 or 3 entered the DBA phase. During the DBA low dose phase participants weighing 18 to &lt; or =23 kg, &gt;23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 900, 1200, 1800, and 2400 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 8 weeks respectively.</description>
        </group>
        <group group_id="P2">
          <title>Double-Blind Acute (DBA) Phase: High Dose</title>
          <description>Participants with partial UC-DAI &gt; or =2 and mucosal appearance = 2 or 3 entered the DBA phase. During the DBA high dose phase participants weighing 18 to &lt; or =23 kg, &gt; 23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 1800, 2400, 3600, and 4800 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 8 weeks respectively.</description>
        </group>
        <group group_id="P3">
          <title>Open-Label Acute Phase (OLA): High Dose</title>
          <description>During the OLA High dose phase participants weighing 18 to &lt;=23 kg, &gt; 23 to &lt; or =35 kg, &gt;35 to &lt; or = 50 kg, &gt; 50 to &lt; or = 90 kg received 1800, 2400, 3600, and 4800 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 8 weeks respectively.</description>
        </group>
        <group group_id="P4">
          <title>Double-Blind Maintenance (DBM) Phase: Low Dose</title>
          <description>Participants with partial UC-DAI &lt; or =1 and mucosal appearance = 0 or 1 entered the DBM phase directly. Also, participants with a clinical response (partial UC-DAI &lt; or =1) after completion of DBA phase or OLA phase entered into the DBM phase. During the DBM low dose phase participants weighing 18 to &lt; or =23 kg, &gt; 23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 900, 1200, 1800, and 2400 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 26 weeks respectively.</description>
        </group>
        <group group_id="P5">
          <title>Double-Blind Maintenance (DBM) Phase: High Dose</title>
          <description>Participants with partial UC-DAI &lt; or =1 and mucosal appearance = 0 or 1 entered the DBM phase directly. Also, participants with a clinical response (partial UC-DAI &lt; or =1) after completion of DBA phase or OLA phase entered into the DBM phase. During the DBM high dose phase participants weighing 18 to &lt;=23 kg, &gt; 23 to &lt; or =35 kg, &gt;35 to &lt; or = 50 kg, &gt; 50 to &lt; or = 90 kg received 1800, 2400, 3600, and 4800 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 26 weeks respectively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double Blind Acute Phase (8 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subjects who Continued in the Study</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label Acute Phase (8 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Entered OLA Via DBA</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double Blind Maintenance Phase(26 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="42"/>
                <participants group_id="P5" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Entered Directly to DBM</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Entered DBM Via DBA</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Entered DBM Via OLA</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other (unspecified)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product. Few participants had multiple movement within the arms of the study at different levels and unique participants baseline was not analysed, only overall participant data was planned, analysed and reported to avoid double-counting.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Participants with partial UC-DAI &gt; or =2 and mucosal appearance = 2 or 3 entered the DBA phase; with UC-DAI between 1 and 2 entered the OLA phase, after completing DBA phase; with UC-DAI &lt; or = 1 and mucosal appearance = 0 or 1 entered the DBM phase directly. Also, participants who had a clinical response (partial UC-DAI &lt; or =1) after completion of DBA phase or OLA phase entered into the DBM phase. During the DBA and DBM phase, participants received 900 to 2400 mg/day (low dose) and 1800 to 4800 mg/day (high dose) of MMX mesalamine/mesalazine tablet orally once daily for 8 and 26 weeks respectively. During OLA phase, participants received the high dose for 8 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.1" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Response During Double-Blind Acute Phase at Week 8</title>
        <description>Clinical response was defined as partial ulcerative colitis disease activity index (UC-DAI) score &lt; or =1 with rectal bleeding = 0, stool frequency &lt; or =1, and physician's global assessment (PGA = 0). Number of participants with clinical response were reported.</description>
        <time_frame>Week 8</time_frame>
        <population>Double-blind acute phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind acute phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-Blind Acute (DBA) Phase: Low Dose</title>
            <description>Participants with partial UC-DAI &gt; or =2 and mucosal appearance = 2 or 3 entered the DBA phase. During the DBA low dose phase participants weighing 18 to &lt; or =23 kg, &gt;23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 900, 1200, 1800, and 2400 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 8 weeks respectively.</description>
          </group>
          <group group_id="O2">
            <title>Double-Blind Acute (DBA) Phase: High Dose</title>
            <description>Participants with partial UC-DAI &gt; or =2 and mucosal appearance = 2 or 3 entered the DBA phase. During the DBA high dose phase participants weighing 18 to &lt; or =23 kg, &gt; 23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 1800, 2400, 3600, and 4800 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 8 weeks respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Response During Double-Blind Acute Phase at Week 8</title>
          <description>Clinical response was defined as partial ulcerative colitis disease activity index (UC-DAI) score &lt; or =1 with rectal bleeding = 0, stool frequency &lt; or =1, and physician's global assessment (PGA = 0). Number of participants with clinical response were reported.</description>
          <population>Double-blind acute phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind acute phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study is not powered to detect differences between treatment groups and other sensitivity analysis (last observation carried forward [LOCF] and complete case) intended to examine the robustness of the treatment estimate. This was an estimation study, and p-values were presented as descriptive statistics.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>Uncorrected Chi-squared Test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>9.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Response During Double-blind Maintenance Phase at Week 26</title>
        <description>Clinical response was defined as partial UC-DAI &lt;=1 with (rectal bleeding = 0, stool frequency &lt; or =1, and PGA = 0). Number of participants who had maintained clinical response were reported.</description>
        <time_frame>Week 26</time_frame>
        <population>Double-blind maintenance phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind maintenance phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-Blind Maintenance (DBM) Phase: Low Dose</title>
            <description>Participants with partial UC-DAI &lt; or =1 and mucosal appearance = 0 or 1 entered the DBM phase directly. Also, participants with a clinical response (partial UC-DAI &lt; or =1) after completion of DBA phase or OLA phase entered into the DBM phase. During the DBM low dose phase participants weighing 18 to &lt;=23 kg, &gt;23 to &lt;=35 kg, &gt;35 to &lt; or =50 kg, &gt;50 to &lt; or =90 kg received 900, 1200, 1800, and 2400 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 26 weeks respectively.</description>
          </group>
          <group group_id="O2">
            <title>Double-Blind Maintenance (DBM) Phase: High Dose</title>
            <description>Participants with partial UC-DAI &lt; or =1 and mucosal appearance = 0 or 1 entered the DBM phase directly. Also, participants with a clinical response (partial UC-DAI &lt; or =1) after completion of DBA phase or OLA phase entered into the DBM phase. During the DBM high dose phase participants weighing 18 to &lt;=23 kg, &gt;23 to &lt;=35 kg, &gt;35 to &lt; or =50 kg, &gt;50 to &lt; or =90 kg received 1800, 2400, 3600, and 4800 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 26 weeks respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Response During Double-blind Maintenance Phase at Week 26</title>
          <description>Clinical response was defined as partial UC-DAI &lt;=1 with (rectal bleeding = 0, stool frequency &lt; or =1, and PGA = 0). Number of participants who had maintained clinical response were reported.</description>
          <population>Double-blind maintenance phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind maintenance phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study is not powered to detect differences between treatment groups and other sensitivity analysis (LOCF and complete case) intended to examine the robustness of the treatment estimate. This was an estimation study, and p-value s were presented as descriptive statistics.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.981</p_value>
            <p_value_desc>P-value were based on a Cochran-Mantel-Haenszel test stratified by prior response status.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>2.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical and Endoscopic Response During Double Blind Acute Phase at Week 8 Using Central Reading</title>
        <description>Clinical and endoscopic response was defined as UC-DAI &lt;=2 with rectal bleeding = 0 and stool frequency &lt;=1, and PGA = 0, and with mucosal healing (endoscopy score &lt;=1) at least a 1 point reduction in endoscopy score from baseline based on central reading. Participants with missing data at week 8 were assumed not to had a clinical response. Participants who completed week 8 but did not have central reading endoscopies at both baseline and week 8 were excluded. Number of participants with clinical and endoscopic response were reported.</description>
        <time_frame>Week 8</time_frame>
        <population>Double-blind acute phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind acute phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-Blind Acute (DBA) Phase: Low Dose</title>
            <description>Participants with partial UC-DAI &gt; or =2 and mucosal appearance = 2 or 3 entered the DBA phase. During the DBA low dose phase participants weighing 18 to &lt; or =23 kg, &gt; 23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 900, 1200, 1800, and 2400 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 8 weeks respectively.</description>
          </group>
          <group group_id="O2">
            <title>Double-Blind Acute (DBA) Phase: High Dose</title>
            <description>Participants with partial UC-DAI &gt; or =2 and mucosal appearance = 2 or 3 entered the DBA phase. During the DBA high dose phase participants weighing 18 to &lt; or =23 kg, &gt; 23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 1800, 2400, 3600, and 4800 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 8 weeks respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical and Endoscopic Response During Double Blind Acute Phase at Week 8 Using Central Reading</title>
          <description>Clinical and endoscopic response was defined as UC-DAI &lt;=2 with rectal bleeding = 0 and stool frequency &lt;=1, and PGA = 0, and with mucosal healing (endoscopy score &lt;=1) at least a 1 point reduction in endoscopy score from baseline based on central reading. Participants with missing data at week 8 were assumed not to had a clinical response. Participants who completed week 8 but did not have central reading endoscopies at both baseline and week 8 were excluded. Number of participants with clinical and endoscopic response were reported.</description>
          <population>Double-blind acute phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind acute phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study is not powered to detect differences between treatment groups and other sensitivity analysis (LOCF and complete case) intended to examine the robustness of the treatment estimate. This was an estimation study, and p-values were presented as descriptive statistics.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.400</p_value>
            <p_value_desc>P-value was calculated based on Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Difference in proportions</param_type>
            <param_value>50.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.3</ci_lower_limit>
            <ci_upper_limit>100.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical and Endoscopic Response During Double Blind Acute Phase at Week 8 Using Local Reading</title>
        <description>Clinical and endoscopic response was defined as UC-DAI &lt; or =2 with rectal bleeding = 0 and stool frequency &lt; or =1, and PGA = 0, and with mucosal healing (endoscopy score &lt; or =1) at least a 1 point reduction in endoscopy score from baseline based on local reading. Participants with missing data at week 8 were assumed not to had a clinical response. Participants who completed week 8 but did not have local reading endoscopies at both baseline and week 8 were excluded. Number of participants with clinical and endoscopic response were reported.</description>
        <time_frame>Week 8</time_frame>
        <population>Double-blind acute phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind acute phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-Blind Acute (DBA) Phase: Low Dose</title>
            <description>Participants with partial UC-DAI &gt; or =2 and mucosal appearance = 2 or 3 entered the DBA phase. During the DBA low dose phase participants weighing 18 to &lt; or =23 kg, &gt; 23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 900, 1200, 1800, and 2400 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 8 weeks respectively.</description>
          </group>
          <group group_id="O2">
            <title>Double-Blind Acute (DBA) Phase: High Dose</title>
            <description>Participants with partial UC-DAI &gt; or =2 and mucosal appearance = 2 or 3 entered the DBA phase. During the DBA high dose phase participants weighing 18 to &lt; or =23 kg, &gt; 23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 1800, 2400, 3600, and 4800 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 8 weeks respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical and Endoscopic Response During Double Blind Acute Phase at Week 8 Using Local Reading</title>
          <description>Clinical and endoscopic response was defined as UC-DAI &lt; or =2 with rectal bleeding = 0 and stool frequency &lt; or =1, and PGA = 0, and with mucosal healing (endoscopy score &lt; or =1) at least a 1 point reduction in endoscopy score from baseline based on local reading. Participants with missing data at week 8 were assumed not to had a clinical response. Participants who completed week 8 but did not have local reading endoscopies at both baseline and week 8 were excluded. Number of participants with clinical and endoscopic response were reported.</description>
          <population>Double-blind acute phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind acute phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study is not powered to detect differences between treatment groups and other sensitivity analysis (LOCF and complete case) intended to examine the robustness of the treatment estimate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.333</p_value>
            <p_value_desc>P-value was based on a Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Difference in proportions</param_type>
            <param_value>50.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.3</ci_lower_limit>
            <ci_upper_limit>100.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Ulcerative Colitis Scale (DUCS) Score During Double-Blind Acute Phase</title>
        <description>DUCS score was to measure 7 specific signs or symptom and one impact (abdominal pain, nocturnal stool, daytime stool, blood in stool, diarrhea, urgency, tiredness) of UC with each item score ranged from 0 (worst) to 10 (best) with the overall score ranged from 0 (worst) to 70 (best) based on the responses. Change in the DUCS score from baseline to Week 8 during DBA phase were reported.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Double-blind acute phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind acute phase. Here, number of participants analyzed signifies participants who were evaluable for this measure category.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-Blind Acute (DBA) Phase: Low Dose</title>
            <description>Participants with partial UC-DAI &gt; or =2 and mucosal appearance = 2 or 3 entered the DBA phase. During the DBA low dose phase participants weighing 18 to &lt; or =23 kg, &gt; 23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 900, 1200, 1800, and 2400 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 8 weeks respectively.</description>
          </group>
          <group group_id="O2">
            <title>Double-Blind Acute (DBA) Phase: High Dose</title>
            <description>Participants with partial UC-DAI &gt; or =2 and mucosal appearance = 2 or 3 entered the DBA phase. During the DBA high dose phase participants weighing 18 to &lt; or =23 kg, &gt; 23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 1800, 2400, 3600, and 4800 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 8 weeks respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Ulcerative Colitis Scale (DUCS) Score During Double-Blind Acute Phase</title>
          <description>DUCS score was to measure 7 specific signs or symptom and one impact (abdominal pain, nocturnal stool, daytime stool, blood in stool, diarrhea, urgency, tiredness) of UC with each item score ranged from 0 (worst) to 10 (best) with the overall score ranged from 0 (worst) to 70 (best) based on the responses. Change in the DUCS score from baseline to Week 8 during DBA phase were reported.</description>
          <population>Double-blind acute phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind acute phase. Here, number of participants analyzed signifies participants who were evaluable for this measure category.</population>
          <units>Score on the scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" spread="2.86"/>
                    <measurement group_id="O2" value="31.6" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.1" spread="3.80"/>
                    <measurement group_id="O2" value="-13.2" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.6" spread="3.96"/>
                    <measurement group_id="O2" value="-16.7" spread="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.2" spread="4.40"/>
                    <measurement group_id="O2" value="-23.1" spread="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study is not powered to detect differences between treatment groups and other sensitivity analysis (LOCF and complete case) intended to examine the robustness of the treatment estimate. This was an estimation study, and p-values were presented as descriptive statistics.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.168</p_value>
            <p_value_desc>P-value is based on an analysis of covariance (ANCOVA) including treatment arm as a factor and baseline DUCS score as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in Least squares Mean</param_type>
            <param_value>-5.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.1</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Improvement in Pediatric Ulcerative Colitis Activity Index (PUCAI) Score During Double-blind Acute Phase at Week 8</title>
        <description>PUCAI was a physician-administered measure that focuses on 6 key signs and symptoms of UC and activity limitations producing a total score ranging from 0-85 with higher scores being worse. Recommended cut-off scores to differentiate disease activity are &lt; 10 (remission); 11-30 (mild); 31-64 (moderate) and &gt; 65 (severe). Participants with an improvement (change of greater than or equal to [&gt; or =] 20 points) in PUCAI score. Number of participants with improvement in PUCAI score during Double-blind Acute Phase at Week 8 were reported.</description>
        <time_frame>Week 8</time_frame>
        <population>Double-blind acute phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind acute phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-Blind Acute (DBA) Phase: Low Dose</title>
            <description>Participants with partial UC-DAI &gt; or =2 and mucosal appearance = 2 or 3 entered the DBA phase. During the DBA low dose phase participants weighing 18 to &lt; or =23 kg, &gt; 23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 900, 1200, 1800, and 2400 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 8 weeks respectively.</description>
          </group>
          <group group_id="O2">
            <title>Double-Blind Acute (DBA) Phase: High Dose</title>
            <description>Participants with partial UC-DAI &gt; or =2 and mucosal appearance = 2 or 3 entered the DBA phase. During the DBA high dose phase participants weighing 18 to &lt; or =23 kg, &gt; 23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 1800, 2400, 3600, and 4800 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 8 weeks respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement in Pediatric Ulcerative Colitis Activity Index (PUCAI) Score During Double-blind Acute Phase at Week 8</title>
          <description>PUCAI was a physician-administered measure that focuses on 6 key signs and symptoms of UC and activity limitations producing a total score ranging from 0-85 with higher scores being worse. Recommended cut-off scores to differentiate disease activity are &lt; 10 (remission); 11-30 (mild); 31-64 (moderate) and &gt; 65 (severe). Participants with an improvement (change of greater than or equal to [&gt; or =] 20 points) in PUCAI score. Number of participants with improvement in PUCAI score during Double-blind Acute Phase at Week 8 were reported.</description>
          <population>Double-blind acute phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind acute phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study is not powered to detect differences between treatment groups and other sensitivity analysis (LOCF and complete case) intended to examine the robustness of the treatment estimate. This was an estimation study, and p-values were presented as descriptive statistics.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.131</p_value>
            <p_value_desc>P-value was based on a continuity-corrected chi-squared test. PUCAI Score was compared between treatment arms using a continuity corrected chi-squared test. Expected cell counts are very low (&lt; 5), then Fisher’s Exact Test is alternative method.</p_value_desc>
            <method>Chi-squared, Corrected</method>
            <param_type>Difference in proportions</param_type>
            <param_value>24.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>50.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical and Endoscopic Response During Double-Blind Maintenance Phase at Week 26 Using Central Reading</title>
        <description>Clinical and endoscopic response was defined as UC-DAI &lt; or =2 with rectal bleeding=0, stool frequency &lt; or =1, PGA=0, and with mucosal healing (endoscopy score &lt; or =1) based on central reading at Week 26. Number of participants with clinical and endoscopic response during double-blind maintenance phase at Week 26 using central reading were reported.</description>
        <time_frame>Week 26</time_frame>
        <population>Double-blind maintenance phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind maintenance phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-Blind Maintenance (DBM) Phase: Low Dose</title>
            <description>Participants with partial UC-DAI &lt; or =1 and mucosal appearance = 0 or 1 entered the DBM phase directly. Also, participants with a clinical response (partial UC-DAI &lt; or =1) after completion of DBA phase or OLA phase entered into the DBM phase. During the DBM low dose phase participants weighing 18 to &lt; or =23 kg, &gt; 23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 900, 1200, 1800, and 2400 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 26 weeks respectively.</description>
          </group>
          <group group_id="O2">
            <title>Double-Blind Maintenance (DBM) Phase: High Dose</title>
            <description>Participants with partial UC-DAI &lt; or =1 and mucosal appearance = 0 or 1 entered the DBM phase directly. Also, participants with a clinical response (partial UC-DAI &lt; or =1) after completion of DBA phase or OLA phase entered into the DBM phase. During the DBM high dose phase participants weighing 18 to &lt;=23 kg, &gt; 23 to &lt; or =35 kg, &gt;35 to &lt; or = 50 kg, &gt; 50 to &lt; or = 90 kg received 1800, 2400, 3600, and 4800 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 26 weeks respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical and Endoscopic Response During Double-Blind Maintenance Phase at Week 26 Using Central Reading</title>
          <description>Clinical and endoscopic response was defined as UC-DAI &lt; or =2 with rectal bleeding=0, stool frequency &lt; or =1, PGA=0, and with mucosal healing (endoscopy score &lt; or =1) based on central reading at Week 26. Number of participants with clinical and endoscopic response during double-blind maintenance phase at Week 26 using central reading were reported.</description>
          <population>Double-blind maintenance phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind maintenance phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study is not powered to detect differences between treatment groups and other sensitivity analysis (LOCF and complete case) intended to examine the robustness of the treatment estimate. This was an estimation study, and p-values were presented as descriptive statistics.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.539</p_value>
            <p_value_desc>P-value is based on a CMH test adjusted by prior response status.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Proportions Percentage</param_type>
            <param_value>-6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.3</ci_lower_limit>
            <ci_upper_limit>12.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical and Endoscopic Response During Double-Blind Maintenance Phase at Week 26 Using Local Reading</title>
        <description>Clinical and endoscopic response was defined as UC-DAI &lt; or = 2 with rectal bleeding=0, stool frequency &lt; or = 1, PGA=0, and with mucosal healing (endoscopy score &lt; or = 1) based on local reading. Number of participants who had maintained clinical and endoscopic response during double-blind maintenance phase at week 26 using local reading were reported.</description>
        <time_frame>Week 26</time_frame>
        <population>Double-blind maintenance phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind maintenance phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-Blind Maintenance (DBM) Phase: Low Dose</title>
            <description>Participants with partial UC-DAI &lt; or =1 and mucosal appearance = 0 or 1 entered the DBM phase directly. Also, participants with a clinical response (partial UC-DAI &lt; or =1) after completion of DBA phase or OLA phase entered into the DBM phase. During the DBM low dose phase participants weighing 18 to &lt; or =23 kg, &gt; 23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 900, 1200, 1800, and 2400 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 26 weeks respectively.</description>
          </group>
          <group group_id="O2">
            <title>Double-Blind Maintenance (DBM) Phase: High Dose</title>
            <description>Participants with partial UC-DAI &lt; or =1 and mucosal appearance = 0 or 1 entered the DBM phase directly. Also, participants with a clinical response (partial UC-DAI &lt; or =1) after completion of DBA phase or OLA phase entered into the DBM phase. During the DBM high dose phase participants weighing 18 to &lt; or =23 kg, &gt; 23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 1800, 2400, 3600, and 4800 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 26 weeks respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical and Endoscopic Response During Double-Blind Maintenance Phase at Week 26 Using Local Reading</title>
          <description>Clinical and endoscopic response was defined as UC-DAI &lt; or = 2 with rectal bleeding=0, stool frequency &lt; or = 1, PGA=0, and with mucosal healing (endoscopy score &lt; or = 1) based on local reading. Number of participants who had maintained clinical and endoscopic response during double-blind maintenance phase at week 26 using local reading were reported.</description>
          <population>Double-blind maintenance phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind maintenance phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study is not powered to detect differences between treatment groups and other sensitivity analysis (LOCF and complete case) intended to examine the robustness of the treatment estimate. This was an estimation study, and p-values were presented as descriptive statistics.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.129</p_value>
            <p_value_desc>P-value was based on a Cochran-Mantel-Haenszel (CMH) test adjusted by prior response status.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in proportions</param_type>
            <param_value>-16.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.0</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Ulcerative Colitis Scale (DUCS) Score During Double-Blind Maintenance Phase</title>
        <description>DUCS score was to measure 7 specific signs or symptom and one impact (abdominal pain, nocturnal stool, daytime stool, blood in stool, diarrhea, urgency, tiredness) of UC with each score range from 0 (worst) to 10 (best) with the overall score ranging from 0 (worst) to 70 (best) based on the responses. Change from Baseline in DUCS score during double-blind maintenance phase at week 13 and Week 26 wwere reported.</description>
        <time_frame>Baseline, Week 13, and Week 26</time_frame>
        <population>Double-blind maintenance phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind maintenance phase. Here, number of participants analyzed signifies participants who were evaluable for this measure category.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-Blind Maintenance (DBM) Phase: Low Dose</title>
            <description>Participants with partial UC-DAI &lt; or =1 and mucosal appearance = 0 or 1 entered the DBM phase directly. Also, participants with a clinical response (partial UC-DAI &lt; or =1) after completion of DBA phase or OLA phase entered into the DBM phase. During the DBM low dose phase participants weighing 18 to &lt;=23 kg, &gt;23 to &lt;=35 kg, &gt;35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 900, 1200, 1800, and 2400 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 26 weeks respectively.</description>
          </group>
          <group group_id="O2">
            <title>Double-Blind Maintenance (DBM) Phase: High Dose</title>
            <description>Participants with partial UC-DAI &lt; or =1 and mucosal appearance = 0 or 1 entered the DBM phase directly. Also, participants with a clinical response (partial UC-DAI &lt; or =1) after completion of DBA phase or OLA phase entered into the DBM phase. During the DBM high dose phase participants weighing 18 to &lt; or =23 kg, &gt; 23 to &lt; or =35 kg, &gt; 35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 1800, 2400, 3600, and 4800 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 26 weeks respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Ulcerative Colitis Scale (DUCS) Score During Double-Blind Maintenance Phase</title>
          <description>DUCS score was to measure 7 specific signs or symptom and one impact (abdominal pain, nocturnal stool, daytime stool, blood in stool, diarrhea, urgency, tiredness) of UC with each score range from 0 (worst) to 10 (best) with the overall score ranging from 0 (worst) to 70 (best) based on the responses. Change from Baseline in DUCS score during double-blind maintenance phase at week 13 and Week 26 wwere reported.</description>
          <population>Double-blind maintenance phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind maintenance phase. Here, number of participants analyzed signifies participants who were evaluable for this measure category.</population>
          <units>Score on the scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="1.37"/>
                    <measurement group_id="O2" value="4.6" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.61"/>
                    <measurement group_id="O2" value="-0.1" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.19"/>
                    <measurement group_id="O2" value="4.4" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study is not powered to detect differences between treatment groups and other sensitivity analysis (LOCF and complete case) intended to examine the robustness of the treatment estimate. This was an estimation study, and p-values were presented as descriptive statistics.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.182</p_value>
            <p_value_desc>P-value was based on an analysis of covariance (ANCOVA) including treatment arm and with prior response status.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in Least squares Mean</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Remission at Pediatric Ulcerative Colitis Activity Index (PUCAI) Score During Double-Blind Maintenance Phase at Week 26</title>
        <description>PUCAI was a physician-administered measure that focuses on 6 key signs and symptoms of UC and activity limitations producing a total score ranging from 0-85 with higher scores being worse. Recommended cut-off scores to differentiate disease activity are &lt; 10 (remission); 11-30 (mild); 31-64 (moderate) and &gt; 65 (severe). Number of participants with remission at PUCAI score during double-blind maintenance phase at week 26 were reported.</description>
        <time_frame>Week 26</time_frame>
        <population>Double-blind maintenance phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind maintenance phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-Blind Maintenance (DBM) Phase: Low Dose</title>
            <description>Participants with partial UC-DAI &lt; or =1 and mucosal appearance = 0 or 1 entered the DBM phase directly. Also, participants with a clinical response (partial UC-DAI &lt; or =1) after completion of DBA phase or OLA phase entered into the DBM phase. During the DBM low dose phase participants weighing 18 to &lt;=23 kg, &gt;23 to &lt;=35 kg, &gt;35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 900, 1200, 1800, and 2400 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 26 weeks respectively.</description>
          </group>
          <group group_id="O2">
            <title>Double-Blind Maintenance (DBM) Phase: High Dose</title>
            <description>Participants with partial UC-DAI &lt; or =1 and mucosal appearance = 0 or 1 entered the DBM phase directly. Also, participants with a clinical response (partial UC-DAI &lt; or =1) after completion of DBA phase or OLA phase entered into the DBM phase. During the DBM high dose phase participants weighing 18 to &lt;=23 kg, &gt;23 to &lt;=35 kg, &gt;35 to &lt; or =50 kg, &gt; 50 to &lt; or =90 kg received 1800, 2400, 3600, and 4800 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 26 weeks respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Remission at Pediatric Ulcerative Colitis Activity Index (PUCAI) Score During Double-Blind Maintenance Phase at Week 26</title>
          <description>PUCAI was a physician-administered measure that focuses on 6 key signs and symptoms of UC and activity limitations producing a total score ranging from 0-85 with higher scores being worse. Recommended cut-off scores to differentiate disease activity are &lt; 10 (remission); 11-30 (mild); 31-64 (moderate) and &gt; 65 (severe). Number of participants with remission at PUCAI score during double-blind maintenance phase at week 26 were reported.</description>
          <population>Double-blind maintenance phase safety analysis set consisted of randomized participants who had taken at least 1 dose of investigational product during the double-blind maintenance phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study is not powered to detect differences between treatment groups and other sensitivity analysis (LOCF and complete case) intended to examine the robustness of the treatment estimate. This was an estimation study, and p-values were presented as descriptive statistics.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.194</p_value>
            <p_value_desc>P-value was based on a CMH test adjusted by prior response status. Participants with remission (PUCAI &lt;10) at double-blind maintenance phase at Week 26 was compared between treatment arms using a CMH test stratifying by Week 8 responder status.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in proportions</param_type>
            <param_value>-9.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.1</ci_lower_limit>
            <ci_upper_limit>11.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of study drug administration up to follow-up (up to Week 27)</time_frame>
      <desc>Overall safety analysis set consisted of randomized participants who had taken at least 1 dose of IP.</desc>
      <group_list>
        <group group_id="E1">
          <title>Double-Blind Acute (DBA) Phase: Low Dose</title>
          <description>Participants with partial UC-DAI &gt;=2 and mucosal appearance = 2 or 3 entered the DBA phase. During the DBA low dose phase participants weighing 18 to &lt;=23 kg, &gt;23 to &lt;=35 kg, &gt;35 to &lt;=50 kg, &gt;50 to &lt;=90 kg received 900, 1200, 1800, and 2400 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 8 weeks respectively.</description>
        </group>
        <group group_id="E2">
          <title>Double-Blind Acute (DBA) Phase: High Dose</title>
          <description>Participants with partial UC-DAI &gt;=2 and mucosal appearance = 2 or 3 entered the DBA phase. During the DBA high dose phase participants weighing 18 to &lt;=23 kg, &gt;23 to &lt;=35 kg, &gt;35 to &lt;=50 kg, &gt;50 to &lt;=90 kg received 1800, 2400, 3600, and 4800 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 8 weeks respectively.</description>
        </group>
        <group group_id="E3">
          <title>Open-Label Acute (OLA) Phase: High Dose</title>
          <description>Participants with partial UC-DAI between 1 and 2 entered the OLA phase, after completing DBA phase. Participants weighing 18 to &lt;=23 kg, &gt;23 to &lt;=35 kg, &gt;35 to &lt;=50 kg, &gt;50 to &lt;=90 kg received 1800, 2400, 3600, and 4800 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 8 weeks respectively during the high dose OLA phase.</description>
        </group>
        <group group_id="E4">
          <title>Double-Blind Maintenance (DBM) Phase: Low Dose</title>
          <description>Participants with partial UC-DAI &lt;=1 and mucosal appearance = 0 or 1 entered the DBM phase directly. Also, participants with a clinical response (partial UC-DAI &lt;=1) after completion of DBA phase or OLA phase entered into the DBM phase. During the DBM low dose phase participants weighing 18 to &lt;=23 kg, &gt;23 to &lt;=35 kg, &gt;35 to &lt;=50 kg, &gt;50 to &lt;=90 kg received 900, 1200, 1800, and 2400 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 26 weeks respectively.</description>
        </group>
        <group group_id="E5">
          <title>Double-Blind Maintenance (DBM) Phase: High Dose</title>
          <description>Participants with partial UC-DAI &lt;=1 and mucosal appearance = 0 or 1 entered the DBM phase directly. Also, participants with a clinical response (partial UC-DAI &lt;=1) after completion of DBA phase or OLA phase entered into the DBM phase. During the DBM high dose phase participants weighing 18 to &lt;=3 kg, &gt;23 to &lt;=35 kg, &gt;35 to &lt;=50 kg, &gt;50 to &lt;=90 kg received 1800, 2400, 3600, and 4800 mg/day of MMX mesalamine/mesalazine tablet orally once daily for 26 weeks respectively.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury corneal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Retinal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="8" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" events="6" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire</organization>
      <phone>1 866-842-5335</phone>
      <email>ClinicalTransparency@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

